» Articles » PMID: 25811174

Serum Resistin and Glomerular Filtration Rate in Patients with Type 2 Diabetes

Overview
Journal PLoS One
Date 2015 Mar 27
PMID 25811174
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: High serum levels of the pro-inflammatory adipokine resistin have been associated with decreased renal function in the general population. The goal of this study was to investigate whether such association is also present among diabetic subjects, who are at increased risk of renal function loss.

Methods: The cross-sectional association between serum resistin levels and estimated glomerular filtration rate (eGFR) was investigated in 1,560 type 2 diabetic (T2D) patients of European ancestry comprised in two different cohorts: 762 patients from San Giovanni Rotondo (SGR; Italy) and 798 patients from Boston (US).

Results: Serum resistin was inversely associated with eGFR in SGR [β (SE) for one SD of resistin increment = -1.01 (0.70) ml/min/1.73 m(2), p = 0.019] and in Boston [β (SE) = -5.31 (0.74) ml/min/1.73 m(2), p < 0.001] samples, as well as in the two studies combined [β (SE) = -3.42 (0.52) ml/min/1.73 m(2), p < 0.001]. The association was unaffected by adjustment for smoking habits, BMI, waist circumference, diabetes duration, HbA1c, insulin treatment, hypertension and lipid-lowering therapy: β (SE) for one SD of resistin increment = -1.07 (0.70), p = 0.02; -5.50 (0.88), p < 0.001; and -2.81 (0.55) ml/min/1.73 m(2), p < .001, in SGR, Boston and the two studies combined, respectively. The association was significantly stronger in men than in women (p for resistin-by-gender interaction = 0.003). For each resistin SD increment, the odds of having eGFR < 0 ml/min/1.7 3m(2) increased by 22% (OR = 1.22; 95% CI 1.02-1.44; p = 0.025) in SGR sample, 69% (OR = 1.69; 95% CI 1.38-2.07; p < 0.001) in Boston sample, and 47% (OR = 1.47; 95% CI 1.29-1.68; p < 0.001) in the two studies considered together. Similar associations were observed in the adjusted model: OR 95% CI for each SD resistin increment being 1.23 (1.03-1.46), p = 0.021; 1.52 (1.20-1.92), p < 0.001; 1.33 (1.16-1.53), p < 0.001, in SGR, Boston and the two studies combined, respectively.

Conclusions: This is the first report of an association between high serum resistin and low eGFR in patients with T2D of European ancestry.

Citing Articles

Serum leptin levels in patients with chronic kidney disease and hypertensive heart disease: An observational cross-sectional study.

Ofori E, Adekena C, Boima V, Asare-Anane H, Yorke E, Nyarko E Health Sci Rep. 2023; 6(1):e1053.

PMID: 36698704 PMC: 9851162. DOI: 10.1002/hsr2.1053.


Resistin levels and inflammatory and endothelial dysfunction markers in obese postmenopausal women with type 2 diabetes mellitus.

Giandalia A, Alibrandi A, Giorgianni L, Lo Piano F, Consolo F, Longo Elia G Diabetol Metab Syndr. 2021; 13(1):98.

PMID: 34496965 PMC: 8427860. DOI: 10.1186/s13098-021-00715-7.


Analysis of serum inflammatory mediators in type 2 diabetic patients and their influence on renal function.

Araujo L, da Silva M, da Silva C, Borges M, Palhares H, Rocha L PLoS One. 2020; 15(3):e0229765.

PMID: 32130282 PMC: 7055870. DOI: 10.1371/journal.pone.0229765.


Physical activity increases the resistin concentration in hemodialyzed patients without metabolic syndrome.

Hornik B, Dulawa J, Szewieczek J, Durmala J Diabetes Metab Syndr Obes. 2018; 12:43-57.

PMID: 30588054 PMC: 6302825. DOI: 10.2147/DMSO.S186674.


High serum resistin levels are associated with peripheral artery disease in the hypertensive patients.

Hsu B, Lee C, Yang C, Chen Y, Wang J BMC Cardiovasc Disord. 2017; 17(1):80.

PMID: 28298189 PMC: 5353862. DOI: 10.1186/s12872-017-0517-2.


References
1.
Steppan C, Bailey S, Bhat S, Brown E, Banerjee R, Wright C . The hormone resistin links obesity to diabetes. Nature. 2001; 409(6818):307-12. DOI: 10.1038/35053000. View

2.
Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

3.
Chen J, Muntner P, Hamm L, Jones D, Batuman V, Fonseca V . The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004; 140(3):167-74. DOI: 10.7326/0003-4819-140-3-200402030-00007. View

4.
Shetty G, Economides P, Horton E, Mantzoros C, Veves A . Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 2004; 27(10):2450-7. DOI: 10.2337/diacare.27.10.2450. View

5.
Olkin I, Sampson A . Comparison of meta-analysis versus analysis of variance of individual patient data. Biometrics. 1998; 54(1):317-22. View